Search
Binimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalFDA-approved test. … Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an
Bromotheophylline
go.drugbank.com/drugs/DB14018Approved[A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.
Malathion
go.drugbank.com/drugs/DB00772ApprovedMalathion is an irreversible cholinesterase inhibitor and has low human toxicity. … Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice.
Synonyms: O,O-dimethyl S-1,2-di(ethoxycarbamyl)ethylAlosetron
go.drugbank.com/drugs/DB00969ApprovedWithdrawnIn June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. … Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes.
Thalidomide
go.drugbank.com/drugs/DB01041ApprovedInvestigationalWithdrawnA piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. … Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception
International brands: Pro-ban MArtesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigational[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]
Collagenase clostridium histolyticum
go.drugbank.com/drugs/DB00048ApprovedInvestigational[L14882] The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers. … Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum.
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigational[L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141] … Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells.
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalLifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome).
Cisatracurium
go.drugbank.com/drugs/DB00565ApprovedInvestigational[A243416,A253592] Cisatracurium is an R-cis-R-cis isomer of [atracurium] and has approximately 3 times its neuromuscular blocking potency. … [A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597].
Products: CISATRACURIO MYLAN GENERICS